IL-7 therapy: Oncology and beyond

Time: 11:30 am
day: Day One

Details:

  • NT-I7 (efineptakin alfa, a long-acting human IL-7) clinical development
  • NT-I7 in combination with checkpoint inhibitors
  • Potential clinical biomarkers in IL-7 treatment

Speakers: